Dr. Clay B. Siegall is currently the CEO, President, and Chariman of the Board for Seatlle Genetics. Seattle Genetics was founded by Clay Siegall in 1998 and has since expanded and grown to be the biggest company of its type in the region. Dr. Clay Siegall has always been involved with cancer research and development and Seattle Genetics is dedicated to creating treatments for cancer patients that previously did not respond well to other types of treatments.
Seattle Genetics was able to obtain FDA approval for their first cancer therapy drug Adcetris. This drug is the main producer of revenue from the company. It is currently available in over sixty countries. Seattle Genetics is also currently working on getting FDA approval for several other cancer treatment drugs that are in the final stages of testing.
The company has also licensed ADC technology to some of the pharmaceutical industry giants such as Pfizer, GlaxoSMithKline, Genetech, and several other companies. The licensing alone has been able to generate over $325 million so far. Dr. Siegall has made a vast improvement in the field of cancer treatment and has managed to help many patients that would otherwise have not received effective therapy. He has received numerous prestigious awards due to the hard work and dedication that he has shown in the cancer research field.
Dr. Clay Siegall had previously worked for some very well known companies such as the National Cancer Institute, the National Institutes for Health, and Bristol-Meyers Squibb Pharmaceutical Research Institue before the creations of Seattle Genetics. Dr. Clay Siegall received his B.S. in Zoology at the University of Maryland and then his Ph.D. from George Washington University in the field of Genetics.